Selective TYK2 Inhibitor Compounds for Reduced JAK2 Off-Target Effects

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for TYK2-mediated disorders lack selective inhibitors that effectively target TYK2 without causing side effects associated with the inhibition of other JAK kinases, particularly JAK2.

Innovation Solution

Development of compounds, such as those in Formula (II), (IIa), and (IIb), which selectively inhibit TYK2 activity with potential pharmaceutically relevant properties, including specific substitutions and linkages that minimize off-target effects on JAK2.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If broad JAK kinase inhibition is used to treat TYK2-mediated disorders, then therapeutic efficacy is improved, but side effects increase due to off-target inhibition of other JAK kinases particularly JAK2

Engineering Contradiction:

Improvetherapeutic efficacyVSAvoidside effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent segments the JAK kinase family by developing compounds that specifically target TYK2 while sparing other JAK kinases. The compounds of Formula (I) and Formula (II) are designed with specific structural features that confer selectivity for TYK2, allowing therapeutic intervention in TYK2-mediated disorders without broadly inhibiting the entire JAK family, thereby reducing off-target side effects

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent applies local quality by introducing specific substitutions and modifications at particular positions within the compound structure. The R1-R13 substituents and their specific configurations create localized interactions that enhance TYK2 binding affinity and selectivity, allowing the compound to distinguish TYK2 from other JAK kinases based on subtle structural differences in the binding pocket

Inventive Principle:

Principle #3Local quality

2Object-affected harmful factors

If selective TYK2 inhibition is achieved through specific compound structures, then off-target effects on JAK2 are reduced, but compound complexity increases

Engineering Contradiction:

Improveoff-target effectsVSAvoidcompound complexity

Core Design Contradiction:

Object-affected harmful factorsVSDevice complexity

Solution Approach 1:

The patent extracts the essential structural features required for TYK2 selectivity from the broader class of JAK inhibitors. By identifying and isolating the critical substituents and linkages that confer TYK2 specificity, the patent simplifies the design process while maintaining selectivity, focusing development on key structural elements rather than exhaustive screening of complex variations

Inventive Principle:

Principle #2Taking out (Extraction)

Data Source

PatentUS20250276977A1TYK2 inhibitors and uses thereof

Publication Date: 2025.09.04 ALUMIS INC

AI summary

Described herein are compounds that are useful in treating a TYK2-mediated disorder. In some embodiments, the TYK2-mediated disorder is an autoimmune disorder, an inflammatory disorder, a proliferative disorder, an endocrine disorder, a neurological disorder, or a disorder associated with transplantation.